

OXFORD BIOMEDICA REPORT ENCOURAGING NEW PHASE II TRIAL RESULTS WITH TROVAX® IN PROSTATE CANCER

- Presentation at the Symposium on Targeted Anticancer Therapies (attached)

Oxford, UK - 25 March 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces encouraging new data from its first Phase II trial of TroVax in prostate cancer. TroVax is Oxford BioMedica's lead cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis. The Phase II data were presented by the clinical investigators from the Methodist Hospital in Houston, Texas, at the 6th International Symposium on Targeted Anticancer Therapies on 20 March 2008 in Bethesda, Maryland. This event was organised by the NDDO Research Foundation in a partnership with the US National Cancer Institute (NCI; www.cancer.gov) and the European Society for Medical Oncology (ESMO; www.esmo.org).

In the Phase II trial, 27 patients with metastatic hormone-refractory prostate cancer (HRPC) were treated with TroVax alone (n=14) or TroVax in combination with GM-CSF (n=13). TroVax was well tolerated with no related serious adverse events. Eligibility for the trial included patients with progressive disease and pre-treatment with at least one course of chemotherapy. Of 24 evaluable patients, all mounted robust antibody responses against the targeted tumour antigen, 5T4, and nine patients also showed strong 5T4-specific T-cell responses. Twenty patients (83%) experienced disease stabilisation. The duration of disease stabilisation in patients continues to be assessed and currently ranges from two to more than ten months. As in previous trials of TroVax, the anti-tumour immune response induced by TroVax correlated with clinical benefit. Time to disease progression (TTP) was significantly greater in 5T4-specific T-cell responders compared to non-responders, with a median TTP of 5.6 months versus 2.3 months (p = 0.028). The combination of GM-CSF with TroVax showed similar clinical and immunological responses to TroVax alone.

The principal investigator conducting the trial concluded that the high frequency of 5T4-specific immune responses and the correlation with enhanced TTP are encouraging and warrant further investigation. The same clinical team at the Methodist Hospital has initiated a further Phase II trial of TroVax in approximately 60 patients with HRPC. The trial is randomised and is designed to evaluate TroVax in combination with sanofi-aventis' Taxotere® (docetaxel) as first line therapy versus docetaxel alone. Patients who progress on docetaxel alone will then be treated with TroVax. For more information on this and other ongoing and planned trials, see www.oxfordbiomedica.co.uk/trovax.htm.

Dr Mike McDonald, Oxford BioMedica's Chief Medical Officer, commented on the new data: *"We continue to be encouraged by the clinical data from ongoing trials of TroVax. It is particularly reassuring to see the relationship between the antigen-specific immune response induced by TroVax and clinical benefit in a third tumour type, following similar conclusions in trials in renal and colorectal cancer. We are delighted that the clinical team at the Methodist Hospital are supporting further development of TroVax in this setting. With our partner, sanofi-aventis, we believe that TroVax could play an important role in the treatment of prostate cancer, addressing a significant unmet need for patients."*

- ends -

Return to the [News](#)

Notes

1. **Oxford BioMedica plc**

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange.

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax[®], an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin[®], a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.

2. **TroVax[®]**

TroVax is Oxford BioMedica's novel cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4.

For further information please contact:

Oxford BioMedica plc

Professor [Alan Kingsman](#), Chief Executive

Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited

James Mitford/Gina Gibson

Tel: +44 (0)20 7588 2828

City/Financial Enquiries

[Lisa Baderoon/Mark Court/Mary-Jane Johnson](#)

Tel: +44 (0)20 7466 5000

Buchanan Communications

Scientific/Trade Press Enquiries

[Holly Griffiths/Katja Stout/Claire Mosley](#)
College Hill

Tel: +44 (0)20 7457 2020

US Enquiries

Thomas Fechtner
The Trout Group LLC

Tel: +1 646 378 2900